A placebo-controlled double-blind randomized cross over pilot study of the efficacy and tolerability of abobotulinum toxin A (Dysport) as a treatment for task-dependent upper limb tremor

Brief description of study

The purpose of this study is to investigate the effects of the drug Abobotulinum toxin A (BoNT; Dysport) on individuals diagnosed with task-specific tremor of the upper limb. Task-specific tremor of the upper limb occurs when performing specific tasks for example: writing, holding utensils or playing an instrument. BoNT (Dysport) has shown to be effective in relaxing the overactive muscles in the following disorders: Cervical dystonia (overactive muscles of the neck), Blepharospasm (overactive muscles of the eyes and face), Glabellar lines (wrinkles) and adult and pediatric spasticity of the upper and lower limbs (overactive muscles of the legs) and is approved by the Food and Drug Administration (FDA) for these conditions. Dysport in this study is considered experimental because this drug has not been approved by the FDA for the treatment of task-specific hand tremor. This study will see if the use of BoNT will also relax the overactive muscles that cause task-specific tremor


Clinical Study Identifier: s17-01266
ClinicalTrials.gov Identifier: NCT03136341
Principal Investigator: Steven J. Frucht
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.